(Q37730012)

22 August 2017

1 reference

title

Biochemical markers in Alzheimer's disease clinical trials (English)

1 reference

22 August 2017

0 references

1

Henrik Zetterberg

1 reference

22 August 2017

4

Kaj Blennow

1 reference

22 August 2017

2

Niklas Mattsson

1 reference

22 August 2017

Les M Shaw

3

1 reference

22 August 2017

publication date

1 February 2010

1 reference

22 August 2017

published in

Biomarkers in Medicine

1 reference

22 August 2017

volume

4

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

91-98

1 reference

22 August 2017

1 reference

Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization

21 January 2018

1 reference

A specific amyloid-beta protein assembly in the brain impairs memory

21 January 2018

1 reference

Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway

21 January 2018

1 reference

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

21 January 2018

1 reference

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

21 January 2018

1 reference

Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women

21 January 2018

1 reference

Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly.

21 January 2018

1 reference

Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.

21 January 2018

1 reference

Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.

21 January 2018

1 reference

Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model

21 January 2018

1 reference

How can we recognize "disease modification" effects?

21 January 2018

1 reference

Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

21 January 2018

1 reference

Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype

21 January 2018

1 reference

Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study.

21 January 2018

1 reference

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

21 January 2018

1 reference

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

21 January 2018

1 reference

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

PET imaging of amyloid deposition in patients with mild cognitive impairment

21 January 2018

1 reference

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.

21 January 2018

1 reference

Cerebrospinal fluid markers for prediction of Alzheimer's disease

21 January 2018

1 reference

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

21 January 2018

1 reference

Future screening for incipient Alzheimer's disease--the influence of prevalence on test performance

21 January 2018

1 reference

Longitudinal stability of CSF biomarkers in Alzheimer's disease.

21 January 2018

1 reference

Biochemical markers in persons with preclinical familial Alzheimer disease.

21 January 2018

1 reference

Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease

21 January 2018

1 reference

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

21 January 2018

1 reference

A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease

21 January 2018

1 reference

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.

21 January 2018

1 reference

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers

21 January 2018

1 reference

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

21 January 2018

1 reference

Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio.

21 January 2018

1 reference

Proteome-based plasma biomarkers for Alzheimer's disease

21 January 2018

1 reference

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

21 January 2018

1 reference

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

21 January 2018

1 reference

Detection and management of cognitive impairment in primary care: The Steel Valley Seniors Survey

21 January 2018

1 reference

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials

21 January 2018

1 reference

Mild cognitive impairment as a diagnostic entity

21 January 2018

1 reference

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

Clinical trials in multiple sclerosis: methodological issues

21 January 2018

1 reference

Surrogate markers as a guide to evaluate response to antiretroviral therapy.

21 January 2018

1 reference

The uses of biomarkers in drug development.

21 January 2018

1 reference

Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.

21 January 2018

1 reference

Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[

21 January 2018

1 reference

First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates

21 January 2018

1 reference

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease

21 January 2018

1 reference

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

21 January 2018

1 reference

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system

21 January 2018

1 reference

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

21 January 2018

1 reference

Neurochemical aftermath of amateur boxing.

21 January 2018

1 reference

Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology

21 January 2018

1 reference

Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease.

21 January 2018

1 reference

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report

21 January 2018

1 reference

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

The role of biomarkers in clinical trials for Alzheimer disease

21 January 2018

1 reference

Aspects of beta-amyloid as a biomarker for Alzheimer's disease

21 January 2018

1 reference

CSF biomarkers: pinpointing Alzheimer pathogenesis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/BMM.09.80

1 reference

22 August 2017

1 reference